<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071888</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-002</org_study_id>
    <nct_id>NCT02071888</nct_id>
  </id_info>
  <brief_title>Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors</brief_title>
  <official_title>A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many tumor cells, in contrast to normal cells, have been shown to require the amino acid&#xD;
      glutamine to produce energy for growth and survival. To exploit the dependence of tumors on&#xD;
      glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine&#xD;
      utilization, glutaminase, will be tested in this Phase 1 study in patients with advanced&#xD;
      hematologic malignancies.&#xD;
&#xD;
      This study is an open-label Phase 1 evaluation of CB-839 in subjects with hematological&#xD;
      tumors. Patients will receive CB-839 capsules orally two or three times daily. The study will&#xD;
      be conducted in 2 parts. Part 1 is a dose escalation study to identify the recommended Phase&#xD;
      2 dose and will enroll patients with advanced and/or treatment-refractory Non-Hodgkin's&#xD;
      Lymphoma (NHL), Multiple Myeloma (MM), or Waldenström's macroglobulinemia (WM)&#xD;
&#xD;
      In Part 2, all patients will receive the recommended Phase 2 dose. This part will enroll&#xD;
      patients with advanced and/or treatment-refractory Non-Hodgkin's Lymphoma (NHL), Multiple&#xD;
      Myeloma (MM), or Waldenström's macroglobulinemia (WM). All patients will be assessed for&#xD;
      safety, pharmacokinetics (plasma concentration of drug), pharmacodynamics (inhibition of&#xD;
      glutaminase), biomarkers (biochemical markers that may predict responsiveness in later&#xD;
      studies), and tumor response.&#xD;
&#xD;
      As an extension of Part 2, a cohort of patients with relapsed and refractory MM will be&#xD;
      enrolled to receive low dose dexamethasone and CB-839. A second cohort of patients with&#xD;
      relapsed or refractory disease following at least 2 prior treatment regimens will be enrolled&#xD;
      to receive CB-839 in combination with standard-dose pomalidomide and low-dose dexamethasone&#xD;
      to further evaluate this triple combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of CB-839: Incidence of adverse events</measure>
    <time_frame>Every 21 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood</measure>
    <time_frame>Study Days 1, 15, and 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: % inhibition of glutaminase in blood</measure>
    <time_frame>Study Days 1 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical activity: Change in tumor size from baseline</measure>
    <time_frame>Every 9 weeks (NHL) or 3 weeks (MM and WM), assessed for an expected average of 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Non-Hodgkin's Lymphoma (NHL)</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Waldenstrom's Macroglobulinemia (WM)</condition>
  <condition>Other B-cell NHL Subtypes, Including WM</condition>
  <condition>T-cell NHL</condition>
  <arm_group>
    <arm_group_label>CB-839</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-839 is administered as oral capsules three times daily (TID) or twice daily with food (BIDf) in 21-day cycles until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CB-839 and low dose dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with dexamethasone until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CB-839, pomalidomide, and low dose dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with pomalidomide and dexamethasone until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839</intervention_name>
    <description>Glutaminase inhibitor</description>
    <arm_group_label>CB-839</arm_group_label>
    <arm_group_label>CB-839 and low dose dexamethasone</arm_group_label>
    <arm_group_label>CB-839, pomalidomide, and low dose dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839 and low dose dexamethasone</intervention_name>
    <description>CB-839 and low dose dexamethasone</description>
    <arm_group_label>CB-839 and low dose dexamethasone</arm_group_label>
    <arm_group_label>CB-839, pomalidomide, and low dose dexamethasone</arm_group_label>
    <other_name>CBd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839, pomalidomide, and low dose dexamethasone</intervention_name>
    <description>CB-839, pomalidomide, and low dose dexamethasone</description>
    <arm_group_label>CB-839, pomalidomide, and low dose dexamethasone</arm_group_label>
    <other_name>CBPd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Disease-Specific Inclusion Criteria&#xD;
&#xD;
        Patients must have one of the following diseases that is either relapsed or refractory to 2&#xD;
        or more prior treatments:&#xD;
&#xD;
          -  NHL: At least one measurable lesion&#xD;
&#xD;
          -  WM: Measurable IgM, with a minimum level of ≥ 2x ULN&#xD;
&#xD;
          -  MM: Serum M-protein ≥ 0.5 g/dL and/or urine M-protein ≥ 200 mg/24 hr. In Part 2,&#xD;
             disease that is considered measurable per the IMWG criteria&#xD;
&#xD;
        Other Inclusion Criteria&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1&#xD;
&#xD;
          -  Life Expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate hepatic, renal, cardiac and hematological function&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Any other current malignancy&#xD;
&#xD;
          -  Treatment with an unapproved, investigational therapeutic agent, immunotherapy or&#xD;
             biological therapy within 21 days prior to the first dose of study drug&#xD;
&#xD;
          -  Recent bone marrow transplant&#xD;
&#xD;
          -  Unable to receive medications by mouth&#xD;
&#xD;
          -  Major surgery within 28 days before the first dose of study drug&#xD;
&#xD;
          -  Uncontrolled, active infection; patients who are known to have HIV infection/&#xD;
             seropositivity, Hepatitis A, B, or C, or CMV reactivation&#xD;
&#xD;
          -  Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  Refractory nausea and vomiting or other situation that may preclude adequate&#xD;
             absorption&#xD;
&#xD;
          -  Other conditions that could interfere with treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith W Orford, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theruer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.calithera.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>Waldenstrom's macroglobulinemia</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>glutaminase</keyword>
  <keyword>glutamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

